List of Vumerity drug patents

Vumerity is owned by Biogen Inc.

Vumerity contains Diroximel Fumarate.

Vumerity has a total of 3 drug patents out of which 0 drug patents have expired.

Vumerity was authorised for market use on 29 October, 2019.

Vumerity is available in capsule, delayed release;oral dosage forms.

Vumerity can be used as method of treating multiple sclerosis.

The generics of Vumerity are possible to be released after 20 September, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10080733 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases
Sep, 2033

(10 years from now)

US8669281 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases
Sep, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9090558 BIOGEN INC Prodrugs of fumarates and their use in treating various diseases
Sep, 2033

(10 years from now)

Drugs and Companies using DIROXIMEL FUMARATE ingredient

Market Authorisation Date: 29 October, 2019

Treatment: Method of treating multiple sclerosis

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of VUMERITY before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic